Endocannabinoids in adipocytes during differentiation and their role in glucose uptake

[1]  F. Fezza,et al.  Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. , 2006, Biochimie.

[2]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[3]  F. Fezza,et al.  New insights into endocannabinoid degradation and its therapeutic potential. , 2006, Mini reviews in medicinal chemistry.

[4]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[5]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[6]  B. Barboni,et al.  Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction , 2005, Journal of Cell Science.

[7]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[8]  D. Deutsch,et al.  Anandamide transport: a critical review. , 2005, Life sciences.

[9]  P. Casellas,et al.  Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. , 2005, European journal of pharmacology.

[10]  A. Gerber,et al.  Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) , 2005, International Journal of Obesity.

[11]  B. Cravatt,et al.  Structure and function of fatty acid amide hydrolase. , 2005, Annual review of biochemistry.

[12]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[13]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[14]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[15]  F. Fezza,et al.  Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D activity. , 2005, Analytical biochemistry.

[16]  M. Maccarrone,et al.  Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes , 2005, Cellular and Molecular Life Sciences CMLS.

[17]  J. Herbert,et al.  The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile , 2005, Diabetes, obesity & metabolism.

[18]  Jill M Seargent,et al.  GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation , 2004, British journal of pharmacology.

[19]  R. Russell,et al.  Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. , 2004, American journal of physiology. Endocrinology and metabolism.

[20]  Arya M. Sharma,et al.  Regulation of the nitric oxide system in human adipose tissue Published, JLR Papers in Press, July 1, 2004. DOI 10.1194/jlr.M300322-JLR200 , 2004, Journal of Lipid Research.

[21]  N. Marx,et al.  Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. , 2004, Circulation research.

[22]  V. Marzo,et al.  Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. , 2004 .

[23]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[24]  L. Marnett,et al.  Oxidative metabolism of endocannabinoids by COX-2. , 2004, Current pharmaceutical design.

[25]  C. Hillard,et al.  Cellular accumulation of anandamide: consensus and controversy , 2003, British journal of pharmacology.

[26]  A. Finazzi-Agro’,et al.  The Endocannabinoid System in Human Keratinocytes , 2003, Journal of Biological Chemistry.

[27]  T. Horvath.  Endocannabinoids and the regulation of body fat: the smoke is clearing. , 2003, The Journal of clinical investigation.

[28]  E. Gabazza,et al.  Nitric oxide stimulates glucose transport through insulin-independent GLUT4 translocation in 3T3-L1 adipocytes. , 2003, European journal of endocrinology.

[29]  V. Di Marzo,et al.  Novel selective and metabolically stable inhibitors of anandamide cellular uptake. , 2003, Biochemical pharmacology.

[30]  Brian Vastag,et al.  Experimental drugs take aim at obesity. , 2003, JAMA.

[31]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[32]  D. Cota,et al.  Endogenous cannabinoid system as a modulator of food intake , 2003, International Journal of Obesity.

[33]  L. Petrocellis,et al.  Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response , 2003, Cellular and Molecular Life Sciences CMLS.

[34]  E. Berry,et al.  Tetrahydrocannabinol and endocannabinoids in feeding and appetite. , 2002, Pharmacology & therapeutics.

[35]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Finazzi-Agro’,et al.  Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. , 2002, Journal of medicinal chemistry.

[37]  T. Kirkham,et al.  Observational analysis of feeding induced by Δ9-THC and anandamide , 2002, Physiology & Behavior.

[38]  T. Willson,et al.  Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. , 2002, Biochemistry.

[39]  N. Jamshidi,et al.  Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats , 2001, British journal of pharmacology.

[40]  A. Finazzi-Agro’,et al.  The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism* , 2001, The Journal of Biological Chemistry.

[41]  S. O’Rahilly,et al.  Arachidonic Acid Stimulates Glucose Uptake in 3T3-L1 Adipocytes by Increasing GLUT1 and GLUT4 Levels at the Plasma Membrane , 2001, The Journal of Biological Chemistry.

[42]  V. Di Marzo,et al.  Structure‐activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens , 2001, British journal of pharmacology.

[43]  A. Finazzi-Agro’,et al.  Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide* , 2000, The Journal of Biological Chemistry.

[44]  D. Jump,et al.  Arachidonic acid and PGE2 regulation of hepatic lipogenic gene expression. , 1999, Journal of lipid research.

[45]  W. Campbell,et al.  Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). , 1999, The Journal of pharmacology and experimental therapeutics.

[46]  G. Reaven,et al.  Effect of masoprocol on glucose transport and lipolysis by isolated rat adipocytes. , 1999, Metabolism: clinical and experimental.

[47]  T. Kirkham,et al.  Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors , 1999, Psychopharmacology.

[48]  H. Girouard,et al.  The lack of bimodality in the effects of endogenous and exogenous prostaglandins on fat cell lipolysis in rats. , 1998, Prostaglandins & other lipid mediators.

[49]  A. Marette,et al.  Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. , 1998, American journal of physiology. Endocrinology and metabolism.

[50]  Maria Panico,et al.  Inhibition of NF-κB DNA Binding by Nitric Oxide , 1996 .

[51]  J. Fong,et al.  Arachidonic acid stimulates the intrinsic activity of ubiquitous glucose transporter (GLUT1) in 3T3-L1 adipocytes by a protein kinase C-independent mechanism. , 1996, Cellular signalling.

[52]  A. Makriyannis,et al.  (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. , 1994, Journal of medicinal chemistry.

[53]  L. Axelrod,et al.  Coordinate Control of Lipolysis by Prostaglandin E2 and Prostacyclin in Rat Adipose Tissue , 1992, Diabetes.

[54]  S. Cushman,et al.  Development of an intracellular pool of glucose transporters in 3T3-L1 cells. , 1992, The Journal of biological chemistry.

[55]  Terry D. Lee,et al.  Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. , 1992, Science.

[56]  C. Kahn,et al.  Maintenance of 3T3-L1 cells in culture media containing saturated fatty acids decreases insulin binding and insulin action. , 1981, Biochemical and biophysical research communications.

[57]  J. G. Hamilton,et al.  The effect of 5,8,11,14-eicosatetraynoic acid on lipid metabolism , 1979, Lipids.

[58]  F. Fezza,et al.  The anandamide membrane transporter and the therapeutic implications of its inhibition , 2005 .

[59]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[60]  J. Bauer,et al.  Nitric oxide donors: biochemical pharmacology and therapeutics. , 1995, Advances in pharmacology.

[61]  T. Shen,et al.  Chemical and biological studies on indomethacin, sulindac and their analogs. , 1977, Advances in drug research.